Suppr超能文献

三阴性乳腺癌病变谱:高级别和低级别病变

The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.

作者信息

Geyer Felipe C, Pareja Fresia, Weigelt Britta, Rakha Emad, Ellis Ian O, Schnitt Stuart J, Reis-Filho Jorge S

机构信息

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.

Department of Pathology, Nottingham University, Nottingham, United Kingdom.

出版信息

Am J Pathol. 2017 Oct;187(10):2139-2151. doi: 10.1016/j.ajpath.2017.03.016. Epub 2017 Jul 20.

Abstract

Triple-negative breast cancer is viewed clinically as an aggressive subgroup of breast cancer. In fact, most triple-negative breast cancers are poor-prognosis tumors with a complex genomic landscape. However, triple-negative disease is vastly heterogeneous, encompassing multiple entities with marked genetic, transcriptional, histologic, and clinical differences, with neoplasms in this group ranging from low to high grade. Among the less common low-grade triple-negative lesions, two large subgroups, both with a rather indolent behavior, can be distinguished: a low-grade triple-negative breast neoplasia family, which includes nonobligate precursors of triple-negative breast cancer, and, despite being low-grade, harbors the complex genomic landscape of usual triple-negative breast cancer, and the salivary gland-like tumors of the breast, lacking all the cardinal molecular features of conventional triple-negative breast cancer and underpinned by specific fusion genes or hotspot mutations, which may be of diagnostic and possibly therapeutic utility. Progression to high-grade triple-negative breast cancer likely occurs in both subgroups but at different rates. In this review, we describe the heterogeneity of triple-negative disease, focusing on the histologic and molecular features of the low-grade lesions. Recognition that triple-negative breast cancer is an operational term and that triple-negative disease is heterogeneous and includes low-grade forms driven by distinct sets of genetic alterations is germane to the successful implementation of precision medicine.

摘要

三阴性乳腺癌在临床上被视为乳腺癌的一个侵袭性亚组。事实上,大多数三阴性乳腺癌是预后不良的肿瘤,具有复杂的基因组格局。然而,三阴性疾病具有高度异质性,包含多个具有明显遗传、转录、组织学和临床差异的实体,该组肿瘤从低级别到高级别不等。在不太常见的低级别三阴性病变中,可以区分出两个行为较为惰性的大亚组:一个是低级别三阴性乳腺肿瘤家族,其中包括三阴性乳腺癌的非必需前体,尽管级别较低,但具有常见三阴性乳腺癌复杂的基因组格局;另一个是乳腺唾液腺样肿瘤,缺乏传统三阴性乳腺癌的所有主要分子特征,并由特定的融合基因或热点突变支持,这可能具有诊断和潜在的治疗价值。两个亚组都可能进展为高级别三阴性乳腺癌,但发生率不同。在这篇综述中,我们描述了三阴性疾病的异质性,重点关注低级别病变的组织学和分子特征。认识到三阴性乳腺癌是一个操作性术语,且三阴性疾病具有异质性,包括由不同基因改变驱动的低级别形式,这对于精准医学的成功实施至关重要。

相似文献

1
The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.
Am J Pathol. 2017 Oct;187(10):2139-2151. doi: 10.1016/j.ajpath.2017.03.016. Epub 2017 Jul 20.
2
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.
NPJ Breast Cancer. 2016 Nov 16;2:16036. doi: 10.1038/npjbcancer.2016.36. eCollection 2016.
3
Problematic breast tumors reassessed in light of novel molecular data.
Mod Pathol. 2021 Jan;34(Suppl 1):38-47. doi: 10.1038/s41379-020-00693-7. Epub 2020 Oct 6.
5
Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer.
Breast Cancer Res Treat. 2015 Jun;151(3):541-53. doi: 10.1007/s10549-015-3430-3. Epub 2015 May 16.
6
Salivary gland-like tumors of the breast express basal-type immunohistochemical markers.
Appl Immunohistochem Mol Morphol. 2013 Jul;21(4):283-6. doi: 10.1097/PAI.0b013e31826a277e.
9
Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.
Pathol Oncol Res. 2018 Oct;24(4):701-716. doi: 10.1007/s12253-017-0307-2. Epub 2017 Sep 14.
10

引用本文的文献

6
MMP14 and DDR2 are potential molecular markers for metastatic triple-negative breast cancer.
Sci Rep. 2025 Jul 1;15(1):21630. doi: 10.1038/s41598-025-05538-4.
7
NOTCH1 combined with chemotherapy synergistically inhibits triple-negative breast cancer.
World J Clin Oncol. 2025 Jun 24;16(6):106197. doi: 10.5306/wjco.v16.i6.106197.
9
Prognostic impact of HER2-low expression in triple-negative breast cancer of high-grade special histological type and no special type.
PLoS One. 2025 Jun 13;20(6):e0325715. doi: 10.1371/journal.pone.0325715. eCollection 2025.
10
Clinical Significance of Tumor Grade in Triple-Negative Breast Cancer: A Retrospective Cohort Analysis.
Biomedicines. 2025 May 1;13(5):1100. doi: 10.3390/biomedicines13051100.

本文引用的文献

1
Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.
NPJ Breast Cancer. 2016 Nov 16;2:16036. doi: 10.1038/npjbcancer.2016.36. eCollection 2016.
2
The Landscape of Somatic Genetic Alterations in Metaplastic Breast Carcinomas.
Clin Cancer Res. 2017 Jul 15;23(14):3859-3870. doi: 10.1158/1078-0432.CCR-16-2857. Epub 2017 Feb 2.
3
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear Polarity.
Cancer Res. 2016 Dec 15;76(24):7118-7129. doi: 10.1158/0008-5472.CAN-16-0298. Epub 2016 Oct 20.
6
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Mod Pathol. 2016 Nov;29(11):1292-1305. doi: 10.1038/modpathol.2016.134. Epub 2016 Aug 5.
8
Whole-Exome Sequencing of Salivary Gland Mucoepidermoid Carcinoma.
Clin Cancer Res. 2017 Jan 1;23(1):283-288. doi: 10.1158/1078-0432.CCR-16-0720. Epub 2016 Jun 23.
9
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.
PLoS One. 2016 Jun 16;11(6):e0157368. doi: 10.1371/journal.pone.0157368. eCollection 2016.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验